Stay informed with the latest litigation news. Explore now

Krka competitive analysis

Latest publications and patents of Krka New

Explore the latest publications and patents granted to Krka, showcasing their recent innovations and technological advancements.

Last updated on: Sep 12, 2025
Publication NumberPublication DateTitleLegal Status

Get instant update for new patents of Krka

Nov 22, 2023Pharmaceutical Oral Dosage Forms Comprising Dabigatran Etexilate And Its Pharmaceutically Acceptable SaltsPatent Maintained As Amended
Mar 16, 2022Crystalline Form K Of Rivaroxaban And Process For Its PreparationGranted And Under Opposition
Nov 3, 2021Processes For Crystallization Of RivaroxabanGranted And Under Opposition
Apr 8, 2020Pharmaceutical Oral Dosage Forms Comprising Lercanidipine And Enalapril And Their Pharmaceutically Acceptable SaltsPatent Maintained As Amended

Explore patent oppositions filed by Krka against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Sep 18, 2025
Patent NumberTitleApplicantOpposition Date

Get instant updates on new opposition filings by the company

New Use Of A Combination Of An Angiotensin Receptor Blocker (Arb) With A Neutral Endopeptidase Inhibitor (Nepi)NOVARTISJul 23, 2025
Composition For Nasal Application With Improved StabilityMARIA CLEMENTINE MARTIN KLOSTERFRAU VERTRIEBSGESELLSCHAFTMar 26, 2025
Sacubitril-Valsartan Dosage Regimen For Treating Heart FailureNOVARTISDec 8, 2023
Compositions Of Grapiprant And Methods For Using The SameARATANA THERAPEUTICSSep 21, 2022
Manufacturing Of Semi-Plastic Pharmaceutical Dosage UnitsINTERVETJul 26, 2022
Tablet Formulation Comprising A Peptide And A Delivery AgentNOVO NORDISKJan 14, 2022
Maropitant FormulationLE VETDec 23, 2021
Methods And Compositions For Treating CancerCOUGAR BIOTECHNOLOGYDec 22, 2021
Parasiticidal Oral Veterinary Compositions Comprising Systemically-Acting Active Agents, Methods And Uses ThereofBOEHRINGER INGELHEIM ANIMAL HEALTH USADec 9, 2021
Trans-4-{2-[4-(2,3-Dichlorophenyl)-Piperazin-1-Yl]-Ethyl}-N,N-Dimethylcarbamoyl-Cyclohexylamine For Treating Negative Symptoms Of SchizophreniaRICHTER GEDEON NYRTSep 30, 2021

Explore Krka's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Sep 18, 2025
Patent NumberGrant DateTitleTotal Oppositions
Nov 22, 2023Pharmaceutical Oral Dosage Forms Comprising Dabigatran Etexilate And Its Pharmaceutically Acceptable Salts3
Mar 16, 2022Crystalline Form K Of Rivaroxaban And Process For Its Preparation1
Nov 3, 2021Processes For Crystallization Of Rivaroxaban1
Apr 8, 2020Pharmaceutical Oral Dosage Forms Comprising Lercanidipine And Enalapril And Their Pharmaceutically Acceptable Salts1

Latest PTAB cases involving Krka New

Discover the latest PTAB cases involving Krka, highlighting their recent legal challenges and patent disputes.

Top competitors of Krka

Top competitors of Krka based on patent oppositions.